We evaluated the cytotoxic effects of the currently accepted therapeutic agents (gemcitabine plus cisplatin) and novel targeted compounds (MEK, PI3K and HDAC inhibitors) on the drug sensitivity versus resistance of KRAS mutant and KRAS wild-type cancer cells. This evidence concerns the gene HDAC9 and cancer.